New drug aims to reduce bulging eyes in thyroid disease
NCT ID NCT07113262
First seen Nov 17, 2025 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This Phase 3 trial tests IBI311 (teprotumumab) in 111 people with inactive thyroid eye disease. The main goal is to see if the drug can reduce eye bulging by at least 2 mm after 24 weeks. Participants receive either the drug or a placebo, and the study lasts up to 64 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Medical University
RECRUITINGShenyang, Liaoning, 110801, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI311 (teprotumumab injection)
What this could lead to
If it works, this could provide a treatment option to reduce eye bulging in people with inactive thyroid eye disease.
What could go wrong
This is a Phase 3 trial, but results may not confirm benefit. Side effects are possible, and the treatment may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.